POWER OF ATTORNEY FORM

The shareholder stated below hereby grants Johan Gileus, employed as CFO by InDex Pharmaceuticals Holding AB (publ), or whomever he or she may appoint, to represent and vote for, in accordance with the instructions in Schedule 1 of this power of attorney, all the shareholder's shares in InDex Pharmaceuticals Holding AB (publ), reg. no. 559067-6820, at the annual general meeting on 20 april 2020.

Shareholder					
Name of the shareholder	:	Personal identification number or corporate registration number:			
Postal address:			Number of shares represented:		
Postcode and post town:		Daytime telephone number:			
Date:	Signature:	Clarification of signature:			

The power of attorney must be dated. If issued by a legal entity, the power of attorney must be signed by authorized representative(s) and be accompanied by a registration certificate or, concerning foreign legal entities, corresponding documents evidencing the authorized representative(s) of the shareholder.

The original signed version of this power of attorney form, and a copy of the registration certificate or corresponding documents (if applicable) shall to be sent to InDex Pharmaceuticals Holding AB (publ), Attn: Annika Lindmark, Tomebodavägen 23a, 171 77 Stockholm, Sweden and must reach the proxy no later than 17 April 2020, provided the shareholder no later than 14 April 2020 has given the company a notice of attendance (by proxy) at the general meeting in accordance with the notice of the general meeting. However, a power of attorney which reaches the company no later than 14 April 2020 shall also be considered the shareholder's notice of attendance at the meeting (by proxy). In addition, shareholders must be entered in the shareholders' register, kept by Euroclear Sweden AB (the Swedish Central Securities Depository & Clearing Organisation), on the record day which is 14 April 2020. Shareholders who have their shares registered in the name of a nominee must request temporary entry in the transcription of the register of shareholders kept by Euroclear Sweden AB in order to be entitled to participate and vote for their shares at the meeting. The shareholder must inform the nominee well in advance of Tuesday 14 April 2020, at which time the register entry must have been made.

In Schedule 1, voting instructions to the proxy shall be provided. The shareholder may not instruct the proxy in any other way than by marking one of the available alternatives, and may not set any particular conditions. The power of attorney is void if the shareholder provides any specific instructions (other than marking one of the available alternatives in Schedule 1) or attaches conditions to the power of attorney or the voting instruction. Please note, that if a voting instruction is omitted or is ambiguous in relation to an item on the agenda, the proxy will not vote for your shares with regard to that item. For complete proposals for resolutions, please refer to the notice of the general meeting on www.indexpharma.com.

Should you have any questions, please contact Johan Gileus via e-mail address johan.gileus@indexpharma.com.

This power of attorney may be revoked by written notice to Annika.lindmark@indexpharma.com, via e-mail to annika.lindmark@indexpharma.com, no later than 19 April 2020.

Schedule 1 to the Power of Attorney Form – Voting instructions

Shareholder

Name of the shareholder:	Personal identification number or corporate registration number:
--------------------------	------------------------------------------------------------------

The voting instructions below are provided by the shareholder above, for the resolutions at the annual general meeting on 20 April 2020 in InDex Pharmaceuticals Holding AB (publ), reg. no. 559067-6820, according to the proposed resolutions in the notice of the general meeting.

r - r						
1. Opening of the meeting and election of chairman of the meeting						
		Yes □	No □	Abstain □		
3. Approval of the agenda						
		Yes □	No □	Abstain □		
5. Determination of whether the meeting has been duly convened						
		Yes □	No □	Abstain □		
7. Resolution in respect of:						
,			\	.1		
a)	adoption of the profit and loss statement and the balance sheet as well as of the consolidated profit and loss statement and the	Yes □	No □	Abstain □		
	consolidated profit and loss statement and balance sheet for the					
	group;					
b)	the company's profits or losses according to the adopted balance	Yes □	No □	Abstain □		
	sheet; and					
c)	the members of the board of directors' and the CEO's discharge					
c,	from liability					
	Peter Zerhouni (CEO)	Yes □	No □	Abstain □		
	Wenche Rolfsen (chairman of the board)	Yes □	No □	Abstain □		
	Uli Hacksell (board member)	Yes □	No □	Abstain □		
	Lennart Hansson (board member)	Yes □	No □	Abstain □		
	Stig Lökke Pedersen (board member)	Yes □	No □	Abstain □		
8. Determination of the number of members of the board of directors, and if applicable deputy members of the						
board of directors, as well as of the number of auditors, and if applicable deputy auditors						
		Yes □	No □	Abstain □		
9. Deter	mination of the fees payable to the members of the board of director					
		Yes □	No □	Abstain □		
	etion of members of the board of directors and auditor					
Re-election of Wenche Rolfsen (as board member)		Yes 🗆	No 🗆	Abstain □		
Re-election of Uli Hacksell (as board member)		Yes □	No 🗆	Abstain □		
Re-election of Lennart Hansson (as board member)		Yes 🗆	No 🗆	Abstain 🗆		
	tion of Stig Lökke Pedersen (as board member)	Yes 🗆	No 🗆	Abstain		
	n of Marlene Forsell (as board member)	Yes □	No 🗆	Abstain		
	n of Yilmaz Mahshid (as board member)	Yes 🗆	No □	Abstain □		
	tion of Wenche Rolfsen (as chairman of the board)	Yes 🗆	No □	Abstain □		
Re-election of PricewaterhouseCoopers AB (PWC) (as auditor) Yes \square No \square Abstain \square						
11. Resolution on directed issue of warrants (incentive program) to the Company and/or Subsidiary for transfer to senior executives and other key persons within the incentive program						
transiei	to senior executives and other key persons within the incentive pro-	Yes □	No □	Abstain □		
12. Resolution on directed issue of warrants (incentive program) to the Company and/or Subsidiary for						
transfer to members of the board of directors within the incentive program						
	program	Yes □	No □	Abstain □		